<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897726</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1402-01</org_study_id>
    <nct_id>NCT02897726</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402</brief_title>
  <official_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety of NVP-1402 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the safety and pharmacokinetics of
      NVP-1402 and NVP-1402R in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as randomized, open-label, active-controlled and crossover assignment
      for evaluate and compare the safety and pharmacokinetics of NVP-1402 and NVP-1402R in healthy
      male subjects. The safety assessed through adverse events up to 17 days after administration.
      Additional variables (ECGs, laboratory test, vital signs, so on) will also be recorded and
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Actual">July 3, 2017</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: Cmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma: AUClast</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: AUCinf</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: Tmax</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of plasma: t1/2</measure>
    <time_frame>up to 24 hours after administration</time_frame>
    <description>Terminal half-life of the analyte in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1402 was administered once a day for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1402R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator was administered twice a day for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1402</intervention_name>
    <description>Oral</description>
    <arm_group_label>NVP-1402</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1402R</intervention_name>
    <description>Oral</description>
    <arm_group_label>NVP-1402R</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  No history of clinically significant medical disorder

          -  Capable of consent to participate in the study

        Exclusion Criteria:

          -  History of hypersensitive reactions to study drug or other related drugs

          -  Any significant abnormality found during screening

          -  Any significant medical history

          -  History of alcohol abuse, smoking continuously

          -  History of drug abuse

          -  Clinically significant surgery within 4 weeks prior to administration of the study
             drug

          -  Participation in another clinical trial within 3 months prior to administration of the
             study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Navipharm</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16209</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>August 6, 2017</last_update_submitted>
  <last_update_submitted_qc>August 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

